Researchers have revealed a surprising new side effect linked to GLP-1 agonists, such as Ozempic, Wegovy, Mounjaro and Zepbound.
These popular treatments for diabetes and obesity could interfere with medical imaging, such as PET and CT ("CAT") scans.
CT scans are often used to get detailed internal images to detect injuries, tumors or other abnormalities, according to Cleveland Clinic. A typical use of PET scans is to examine organs and tissues, detect cancer activity or monitor how the body is responding to treatment.
In the case review, presented this week at the 38th Annual Congress of the European Association of Nuclear Medicine in Barcelona, Spain, researchers analyzed cancer scans of patients who were taking GLP-1 medications, according to a press release.
They found some "atypical" scan results that could be mistaken as signs of disease.
"We noticed an unusual uptake in one of our patients on a GLP-1 agonist, which prompted a wider review across our network," lead author Dr. Peter Strouhal, medical director at Alliance Medical Ltd in the U.K., stated in the release.
"We found that these altered patterns are increasingly common, yet there is currently no national or international guidance in the U.K. addressing this emerging issue."
